Do you add trastuzumab to adjuvant chemotherapy for patients with Her2+ stage I-II high grade serous uterine cancer following surgical staging?

No, I don’t routinely add trastuzumab to adjuvant chemotherapy for early stage Her2+ serous endometrial cancer patients. There are no data supporting its use in this manner. My recommendation is to offer her treatment on GY026, a study enrolling both early and late-stage serous endometrial cancer patients (also carcinosarcoma). In the absence of an available clinical trial, I would not be critical of offering a patient trastuzumab after extensive counseling about the absence of data supporting its use in this fashion.

Background:

Approximately 30% of uterine serous carcinomas overexpress Her2/Neu. Similar to breast cancer, its overexpression appears to be a poor prognostic factor. A small, randomized phase II study in advanced (Stage 3-4, rec...